Navigation Links
What to Look for in These Biotech Stocks? Threshold Pharma, Seattle Genetics, Chiasma, and Ophthotech

NEW YORK, May 18, 2016 /PRNewswire/ --

The Biotech industry continues to face a wave of challenges, but it does not mean that there are no opportunities ahead. Today, has on its list these four equities: Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Seattle Genetics Inc. (NASDAQ: SGEN), Chiasma Inc. (NASDAQ: CHMA), and Ophthotech Corp. (NASDAQ: OPHT). Sign up now to receive our free insights and trading alerts at:

Threshold Pharmaceuticals Inc.'s shares gained 0.68%, closing Tuesday's trading session at $0.37. The stock recorded a trading volume of 366,333 shares. The Company's shares have advanced 23.33% in the previous three months and are trading 14.24% below their 50-day moving average. Additionally, shares of Threshold Pharmaceuticals have a Relative Strength Index (RSI) of 40.95. Sign up and activate your free alert on THLD at:

On Tuesday, shares in Seattle Genetics Inc. recorded a trading volume of 2.03 million shares, above their three months average volume of 1.09 million shares. The stock edged 4.73% higher, ending the day at $35.85. The Company's shares have advanced 13.41% in the previous three months. The stock is trading above its 50-day moving average by 1.31%. Furthermore, shares of Seattle Genetics have an RSI of 53.41. The complimentary trade alert on SGEN can be accessed at:

Chiasma Inc.'s stock finished the day 1.06% higher at $2.87 and with a total volume of 380,030 shares traded. The Company's shares are trading below their 50-day moving average by 60.43%. The stock has an RSI of 29.17. Register for free on and activate the trade alert on CHMA at:

Shares in Ophthotech Corp. ended yesterday's session 1.16% higher at $47.02. The stock recorded a trading volume of 416,558 shares. The Company's shares are trading 4.74% above their 50-day moving average. Moreover, Ophthotech's stock has an RSI of 54.86. OPHT free trade alert is just a click away at:


Active Wall Street: 

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

AWS has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

For any questions, inquiries, or comments reach out to us directly at:
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
Phone number:  1-858-257-3144

SOURCE Chelmsford Park SA
Copyright©2016 PR Newswire.
All rights reserved

Related biology technology :

1. These Four Researchers Will Receive $600,000 From Science Center’s QED Proof-of-Concept Program
2. CEM führt neue, bahnbrechende Technologie für Mikrowellen-Peptidsynthese ein
3. Separation Systems for Commercial Biotechnology Market Expected to Reach US$ 19,227.8 Mn in 2023: Transparency Market Research
4. Global Stem Cells Group and University of Santiago Biotech Lab Endorse Asia-Pacific Symposium
5. Race 4 Research 5K and Walk for ALS to Take Place on May 15 in Kendall Square’s Biotech Hub
6. Global Nanobiotechnology Report 2016 - Applications, Markets and Companies Analysis to 2025 -- Research and Markets
7. Maxwell Biotech Venture Funds Portfolio Company Hepatera LLC Announces Start of Phase 2b Clinical Trial of Myrcludex B
8. Desktop Genetics Wins Best Biotech at the SXSW Innovation Awards
9. Global Next-Generation Sequencing (NGS) Market Value of USD 10,371 Million by 2021 - Trends, Technologies & Opportunities Report 2016-2021 - Key Vendors: Gatc Biotech, Macrogen, Qiagen
10. Study: PA Biotech Center of Bucks County Spurs $1.8 Billion in Economic Impact
11. Johns Hopkins Carey Business School Selects Biotechnology Business Leader Dr. Tony Coles as Commencement Speaker
Post Your Comments:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... PA (PRWEB) , ... October 10, 2017 , ... ... City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives ... the award for Excellence in Volunteer Experience from US2020. , US2020’s mission is ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 30.37% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
Breaking Biology News(10 mins):